GlassScriptPhysician profile
Cassandra E Spruill
NPI 1508019308
$1,341.26
in general payments reported to CMS, 2019-2025
15 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $262 · 2023: $885 · 2024: $37.83 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.25 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $201.41 | 2023-2025 | Micra |
| Merck Sharp & Dohme LLC | $185.06 | 2022-2023 | Verquvo |
| Amgen INC. | $181.26 | 2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $149.44 | 2022-2023 | Farxiga, Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $108.37 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.89 | 2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $86.72 | 2022-2023 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $80.71 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.16 | 2022-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $58.25 | 2022-2023 | Xarelto |
| Pfizer INC. | $38.43 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $22.33 | 2024 | Evkeeza |
| Kestra Medical Technology Services, INC. | $20.01 | 2023 | Assure Wcd |
| Bardy Diagnostics, INC. | $19.72 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Spruill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.